Recent phase III data on relatlimab and nivolumab combo versus nivolumab in untreated advanced melanoma showed greater benefit in progression-free survival: 47.7% at 12 months [95% confidence interval (CI), 41.8% to 53.2%] with the PD-1/LAG-3 combination as compared with 36.0% (95% CI, 30.5% to 41.6%) with the anti-PD-1 monotherapy.45 The gene discussed is PDCD1; the disease is melanoma.